17:33 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
01:25 , Jul 14, 2015 |  BC Extra  |  Top Story

Anacor soars on Phase III dermatitis data

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) jumped $47.32 (56%) to $131.93 on Monday after its crisaborole ( AN2728 ) met the primary and secondary endpoints in two Phase III trials to treat atopic dermatitis. Anacor plans to...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

Obagi Medical Products, Valeant Pharmaceuticals deal

Valeant will acquire Obagi for $19.75 per share in cash, or about $344.3 million based on 17.4 million shares outstanding as of March 6. The price is a 28% premium to Obagi's close of $15.39...
07:00 , Aug 1, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Affymax Inc. (NASDAQ:AFFY) lost $0.64 to $6.61 last week after FDA accepted for review an NDA for peginesatide (formerly Hematide ) to treat anemia in chronic kidney disease (CKD) patients on dialysis. Affymax...
00:31 , Jul 28, 2011 |  BC Extra  |  Company News

Meda denies takeover bid

Meda AB (SSE:MEDAA) issued a statement Wednesday that it has not received a takeover approach of the kind described late Tuesday in an article in The Wall Street Journal . The article said partner Valeant...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

HylatopicPlus Emollient Foam: Postmarketing study data

An open-label postmarketing study in 30 patients showed that HylatopicPlus Emollient Foam produced 67.9% improvement in IGA scores vs. 63.1% for Elidel pimecrolimus. At week 4, 82% of patients receiving HylatopicPlus were rated as "clear"...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

Medivir, Valeant Pharmaceuticals, Meda sales and marketing update

Medivir and Meda amended a 2010 commercialization deal for Medivir's Xerese to treat herpes simplex labialis (cold sores) to grant Meda full rights to the product in North America plus exclusive U.S. rights to treat...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Columbia Laboratories Inc. (NASDAQ:CBRX) was off $0.09 to $3.14 last week after FDA accepted for review an NDA for Prochieve vaginal progesterone gel to reduce the risk of preterm birth in women with...